Nurix Therapeutics Net Debt Growth & History (NRIX)
Nurix Therapeutics's net debt was −$191.2M for fiscal 2025.
View full Nurix Therapeutics company overviewNurix Therapeutics annual net debt history
| Fiscal year | Period ended | Net debt | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-11-30 | −$191.2M | −$109.5M | — |
| 2024 | 2024-11-30 | −$81.7M | −$57.7M | — |
| 2023 | 2023-11-30 | −$24.0M | $28.5M | — |
| 2022 | 2022-11-30 | −$52.5M | $15.0M | — |
| 2021 | 2021-11-30 | −$67.5M | — | — |
Nurix Therapeutics quarterly net debt
| Fiscal quarter | Period ended | Net debt | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-05-31 | −$9.5M | $22.8M | — |
| Q1 2026 | 2026-02-28 | −$12.5M | $36.8M | — |
| Q4 2025 | 2025-11-30 | −$191.2M | −$109.5M | — |
| Q3 2025 | 2025-08-31 | −$22.0M | $49.9M | — |
| Q2 2025 | 2025-05-31 | −$32.3M | $55.6M | — |
| Q1 2025 | 2025-02-28 | −$49.3M | −$28.6M | — |
| Q4 2024 | 2024-11-30 | −$81.7M | −$57.7M | — |
| Q3 2024 | 2024-08-31 | −$71.9M | −$37.6M | — |
| Q2 2024 | 2024-05-31 | −$88.0M | −$38.4M | — |
| Q1 2024 | 2024-02-29 | −$20.7M | $2.3M | — |
| Q4 2023 | 2023-11-30 | −$24.0M | $28.5M | — |
| Q3 2023 | 2023-08-31 | −$34.3M | $15,000 | — |
| Q2 2023 | 2023-05-31 | −$49.6M | −$22.6M | — |
| Q1 2023 | 2023-02-28 | −$22.9M | $40.1M | — |
| Q4 2022 | 2022-11-30 | −$52.5M | $15.0M | — |
| Q3 2022 | 2022-08-31 | −$34.3M | — | — |
| Q2 2022 | 2022-05-31 | −$27.0M | — | — |
| Q1 2022 | 2022-02-28 | −$63.0M | — | — |
| Q4 2021 | 2021-11-30 | −$67.5M | — | — |
Nurix Therapeutics net debt trends
Between the periods ended 2021-11-30 and 2025-11-30, Nurix Therapeutics's net debt decreased from −$67.5M to −$191.2M, a change of −$123.8M. The latest reported quarter, Q2 2026, shows −$9.5M.
What net debt means
Net debt compares a company’s interest-bearing debt with its cash and cash equivalents. Positive net debt means debt exceeds cash, while a negative value indicates the company has more cash than debt on this measure.
How net debt is calculated
TickerStat calculates net debt as total interest-bearing debt minus cash and cash equivalents at the same reporting-period end. Short-term investments are not subtracted because they are not included in the standardized cash series. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Nurix Therapeutics source filings ↗